Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company's short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ZSAN
- CUSIP: N/A
- Web: www.zosanopharma.com
- Market Cap: $38.02 million
- Outstanding Shares: 39,230,000
- 50 Day Moving Avg: $0.95
- 200 Day Moving Avg: $0.95
- 52 Week Range: $0.45 - $3.54
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.26
- P/E Growth: 0.000
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.56 per share
- Price / Book: 1.71
- EBIDTA: ($24,930,000.00)
- Return on Equity: -172.90%
- Return on Assets: -89.92%
- Current Ratio: 3.25%
- Quick Ratio: 3.25%
- Average Volume: 859,986 shs.
- Beta: 2.68
- Short Ratio: 18.95
Frequently Asked Questions for Zosano Pharma Corporation (NASDAQ:ZSAN)
What is Zosano Pharma Corporation's stock symbol?
Zosano Pharma Corporation trades on the NASDAQ under the ticker symbol "ZSAN."
How were Zosano Pharma Corporation's earnings last quarter?
Zosano Pharma Corporation (NASDAQ:ZSAN) announced its earnings results on Thursday, August, 10th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.02. During the same quarter in the prior year, the company posted ($0.54) earnings per share. View Zosano Pharma Corporation's Earnings History.
When will Zosano Pharma Corporation make its next earnings announcement?
Where is Zosano Pharma Corporation's stock going? Where will Zosano Pharma Corporation's stock price be in 2017?
2 equities research analysts have issued 12-month price targets for Zosano Pharma Corporation's shares. Their predictions range from $3.00 to $4.00. On average, they expect Zosano Pharma Corporation's share price to reach $3.50 in the next twelve months. View Analyst Ratings for Zosano Pharma Corporation.
Who are some of Zosano Pharma Corporation's key competitors?
Some companies that are related to Zosano Pharma Corporation include Pfenex (PFNX), Rexahn Pharmaceuticals (RNN), Ergomed PLC (ERGO), ImmuPharma PLC (IMM), Applied Genetic Technologies Corporation (AGTC), Akari Therapeutics PLC (AKTX), Flex Pharma (FLKS), Motif Bio PLC (MTFB), TRACON Pharmaceuticals (TCON), Microbot Medical (MBOT), Endocyte (ECYT), Dipexium Pharmaceuticals (PLXP), KemPharm (KMPH), OptiBiotix Health PLC (OPTI), Xenon Pharmaceuticals (XENE), Leap Therapeutics (LPTX), Proteostasis Therapeutics (PTI) and Avacta Group Plc (AVCT).
Who are Zosano Pharma Corporation's key executives?
Zosano Pharma Corporation's management team includes the folowing people:
- John P. Walker, Chairman of the Board, President, Chief Executive Officer
- Georgia L. Erbez, Interim Chief Financial Officer, Chief Business Officer
- Eric Scharin, Vice President - Technical Operations
- Thorsten von Stein M.D. Ph.D., Chief Medical Officer
- Joseph P. Hagan, Director
- Bruce D. Steel, Director
- Troy E. Wilson Ph.D. J.D., Independent Director
- Kleanthis G. Xanthopoulos Ph.D., Independent Director
When did Zosano Pharma Corporation IPO?
(ZSAN) raised $47 million in an initial public offering (IPO) on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.
Who owns Zosano Pharma Corporation stock?
Zosano Pharma Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (4.53%), Vanguard Group Inc. (3.11%), Nexthera Capital LP (1.07%), Victory Capital Management Inc. (0.60%), Granite Point Capital Management L.P. (0.38%) and Geneva Advisors LLC (0.26%). Company insiders that own Zosano Pharma Corporation stock include Donald J Kellerman, Enterprise Associates 12 New, Georgia Erbez, John Peter Walker, Konstantinos Alataris and M James Barrett. View Institutional Ownership Trends for Zosano Pharma Corporation.
Who sold Zosano Pharma Corporation stock? Who is selling Zosano Pharma Corporation stock?
Who bought Zosano Pharma Corporation stock? Who is buying Zosano Pharma Corporation stock?
Zosano Pharma Corporation's stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Northern Trust Corp. Company insiders that have bought Zosano Pharma Corporation stock in the last two years include Donald J Kellerman, Georgia Erbez, John Peter Walker and Konstantinos Alataris. View Insider Buying and Selling for Zosano Pharma Corporation.
How do I buy Zosano Pharma Corporation stock?
Shares of Zosano Pharma Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zosano Pharma Corporation's stock price today?
MarketBeat Community Rating for Zosano Pharma Corporation (NASDAQ ZSAN)MarketBeat's community ratings are surveys of what our community members think about Zosano Pharma Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Zosano Pharma Corporation stock can currently be purchased for approximately $0.96.
Consensus Ratings for Zosano Pharma Corporation (NASDAQ:ZSAN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$3.50 (266.11% upside)|
Analysts' Ratings History for Zosano Pharma Corporation (NASDAQ:ZSAN)
(Data available from 9/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|3/24/2017||Piper Jaffray Companies||Initiated Coverage||Overweight||$4.00||Low|
|3/11/2017||Roth Capital||Set Price Target||Buy||$3.00||Medium|
|8/11/2016||Ladenburg Thalmann Financial Services||Downgrade||Buy -> Neutral||N/A|
Earnings History for Zosano Pharma Corporation (NASDAQ:ZSAN)Earnings History by Quarter for Zosano Pharma Corporation (NASDAQ ZSAN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/12/2015||Q215||($0.53)||($0.63)||$0.22 million||$0.10 million||View||N/A|
Earnings Estimates for Zosano Pharma Corporation (NASDAQ:ZSAN)
2017 EPS Consensus Estimate: ($1.06)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Zosano Pharma Corporation (NASDAQ:ZSAN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Zosano Pharma Corporation (NASDAQ:ZSAN)
Insider Ownership Percentage: 2.95%Insider Trades by Quarter for Zosano Pharma Corporation (NASDAQ:ZSAN)
Institutional Ownership Percentage: 22.66%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/25/2017||Georgia Erbez||CFO||Buy||68,000||$1.32||$89,760.00|| |
|5/25/2017||John Peter Walker||CEO||Buy||73,716||$1.36||$100,253.76|| |
|2/13/2017||Enterprise Associates 12 New||Major Shareholder||Sell||1,099,996||$2.01||$2,210,991.96|| |
|9/16/2016||Enterprise Associates 12 New||Major Shareholder||Sell||7,471||$0.75||$5,603.25|| |
|9/13/2016||Enterprise Associates 12 New||Major Shareholder||Sell||10,000||$0.74||$7,400.00|| |
|8/29/2016||M James Barrett||Major Shareholder||Sell||50,000||$1.01||$50,500.00|| |
|8/24/2016||Enterprise Associates 12 New||Major Shareholder||Sell||1,200||$1.21||$1,452.00|| |
|8/19/2016||Donald J Kellerman||VP||Buy||15,920||$1.32||$21,014.40|| |
|8/19/2016||Georgia Erbez||CFO||Buy||47,750||$1.32||$63,030.00|| |
|8/19/2016||John Peter Walker||Director||Buy||63,700||$1.32||$84,084.00|| |
|8/19/2016||Konstantinos Alataris||CEO||Buy||127,389||$1.32||$168,153.48|| |
|7/21/2016||Enterprise Associates 12 New||Major Shareholder||Sell||23,681||$1.27||$30,074.87|| |
|7/13/2016||Enterprise Associates 12 New||Major Shareholder||Sell||13,382||$1.20||$16,058.40|| |
|1/30/2015||Enterprise Associates 12 New||Major Shareholder||Buy||23,457||$11.00||$258,027.00|| |
Headline Trends for Zosano Pharma Corporation (NASDAQ:ZSAN)
Latest Headlines for Zosano Pharma Corporation (NASDAQ:ZSAN)
|Zosano Presents Data from ZOTRIP Study at International Headache Society|
finance.yahoo.com - September 14 at 12:11 PM
|Zosano Pharma Announces US Patent Office Publication of “Method of Rapidly Achieving Therapeutic Concentrations of Triptans for Treatment of Migraines”|
finance.yahoo.com - August 29 at 10:08 AM
| Analysts Expect Zosano Pharma Corporation (ZSAN) to Announce -$0.15 EPS|
www.americanbankingnews.com - August 25 at 4:10 AM
|Zosano Pharma's (ZSAN) CEO John Walker on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha|
seekingalpha.com - August 12 at 9:06 AM
|Zosano Pharma Corporation (ZSAN) vs. Acorda Therapeutics (ACOR) Head to Head Comparison|
www.americanbankingnews.com - August 11 at 4:58 PM
|Zosano Pharma Reports Second Quarter 2017 Financial Results and Operational Update|
globenewswire.com - August 11 at 9:24 AM
|Zosano Pharma Reports Second Quarter 2017 Financial Results and Operational Update|
finance.yahoo.com - August 11 at 9:24 AM
|Zosano Pharma Corporation (ZSAN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS|
www.americanbankingnews.com - August 10 at 6:21 PM
|Zosano Pharma to Host Conference Call on Second Quarter 2017 Financial Results and Provide Operational Update - GlobeNewswire (press release)|
globenewswire.com - August 4 at 10:21 AM
|Zosano Pharma to Host Conference Call on Second Quarter 2017 Financial Results and Provide Operational Update - Nasdaq|
www.nasdaq.com - August 2 at 9:02 AM
|Zosano Pharma to Host Conference Call on Second Quarter 2017 Financial Results and Provide Operational Update|
finance.yahoo.com - August 2 at 9:02 AM
|Zosano Pharma (ZSAN) Announces Positive Phase 1 Data of Zolmitriptan Delivery - StreetInsider.com|
www.streetinsider.com - August 1 at 8:08 AM
|Zosano Announces Publication of Positive Phase 1 Data of Zolmitriptan Delivery In Future Medicine’s Pain Management Journal|
finance.yahoo.com - August 1 at 8:08 AM
|Zosano Pharma Corporation (ZSAN) to Release Quarterly Earnings on Tuesday|
www.americanbankingnews.com - August 1 at 7:17 AM
|ROTY Edition 1 Volume 11: Our First Sell - Seeking Alpha|
seekingalpha.com - July 13 at 8:40 PM
|Zosano Pharma (ZSAN) Reports Outcome of End of Phase 2 Meetings with FDA - StreetInsider.com|
www.streetinsider.com - June 27 at 9:35 AM
|Zosano Pharma Announces Outcome of End of Phase 2 Meetings with FDA|
finance.yahoo.com - June 27 at 9:35 AM
|Comparing Zosano Pharma Corporation (ZSAN) and GW Pharmaceuticals PLC (GWPH)|
www.americanbankingnews.com - June 24 at 12:14 PM
| Analysts Expect Zosano Pharma Corporation (ZSAN) Will Post Earnings of -$0.15 Per Share|
www.americanbankingnews.com - June 21 at 12:08 PM
|Zosano Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)|
www.globenewswire.com - June 14 at 4:32 PM
|Zosano Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)|
finance.yahoo.com - June 14 at 4:32 PM
|Zosano Pharma (ZSAN) Presents Additional Data from ZOTRIP Study - StreetInsider.com|
www.streetinsider.com - June 12 at 3:16 PM
|Zosano Presents Additional Data from ZOTRIP Study at American Headache Society, Demonstrating Positive Results for Pain Freedom and Sustained Pain Freedom|
finance.yahoo.com - June 12 at 3:16 PM
|Zosano Pharma Corp (ZSAN) Upgraded by ValuEngine to Sell|
www.americanbankingnews.com - June 6 at 6:16 PM
|Zosano to Present Migraine Data at Three Industry-Leading Conferences - GlobeNewswire (press release)|
globenewswire.com - June 2 at 8:18 AM
|Zosano to Present Migraine Data at Three Industry-Leading Conferences|
finance.yahoo.com - June 2 at 8:18 AM
|Zosano Pharma Corp (ZSAN) Interim CEO John Peter Walker Bought $100,254 of Shares|
finance.yahoo.com - May 27 at 6:58 AM
|Zosano Pharma Corp (ZSAN) Expected to Post Earnings of -$0.17 Per Share|
www.americanbankingnews.com - May 26 at 8:55 AM
|Zosano Pharma Corp (ZSAN) CFO Purchases $89,760.00 in Stock|
www.americanbankingnews.com - May 25 at 10:21 PM
|Zosano Pharma Corp (ZSAN) CEO Acquires $100,253.76 in Stock|
www.americanbankingnews.com - May 25 at 10:21 PM
|Zosano Pharma Corp (ZSAN) Announces Earnings Results, Misses Expectations By $0.04 EPS|
www.americanbankingnews.com - May 10 at 5:18 PM
|Biotech Stocks Under Scanner -- Bioverativ, Zosano Pharma, MannKind, and Ocera Therapeutics - PR Newswire (press release)|
www.prnewswire.com - May 10 at 8:45 AM
|Zosano Pharma (ZSAN) Reports Q4 Loss of $0.34; CEO Resigns|
www.streetinsider.com - May 9 at 9:00 PM
|Investor Network: Zosano Pharma Corp. to Host Earnings Call|
finance.yahoo.com - May 9 at 9:00 PM
|Zosano Reports First Quarter 2017 Financial Results and Announces Management Changes|
finance.yahoo.com - May 9 at 9:00 PM
|Zosano Pharma Corp (ZSAN) Set to Announce Quarterly Earnings on Wednesday|
www.americanbankingnews.com - May 8 at 9:00 AM
|Zosano Pharma to Host Conference Call on First Quarter 2017 Financial Results and Provide Operational Update|
feeds.benzinga.com - May 8 at 5:43 AM
|Zosano Pharma Corp (ZSAN) Earns Media Impact Rating of -0.12|
www.americanbankingnews.com - May 4 at 8:20 AM
|Zosano Pharma Corp (ZSAN) Expected to Post Earnings of -$0.30 Per Share|
www.americanbankingnews.com - May 3 at 12:04 AM
|Zosano Pharma Corp (ZSAN) Getting Somewhat Critical News Coverage, Study Finds|
www.americanbankingnews.com - April 29 at 9:16 AM
|Short Interest in Zosano Pharma Corp (ZSAN) Grows By 35.1%|
www.americanbankingnews.com - April 29 at 1:17 AM
|Zosano Pharma Corp (ZSAN) Getting Somewhat Favorable News Coverage, AlphaOne Reports|
www.americanbankingnews.com - April 25 at 3:11 PM
|Zosano Pharma Corp (ZSAN) Receiving Somewhat Negative Media Coverage, Report Shows|
www.americanbankingnews.com - April 20 at 9:17 AM
|Zosano Pharma Corp (ZSAN) Earns Daily Coverage Optimism Rating of -0.10|
www.americanbankingnews.com - April 16 at 8:48 AM
|Zosano Pharma Corp (ZSAN) Earning Somewhat Negative News Coverage, Analysis Finds|
www.americanbankingnews.com - April 13 at 9:21 AM
|Zosano Pharma Corp (ZSAN) Short Interest Down 12.5% in March|
www.americanbankingnews.com - April 12 at 7:17 AM
| Analysts Anticipate Zosano Pharma Corp (ZSAN) Will Post Earnings of -$0.30 Per Share|
www.americanbankingnews.com - April 11 at 6:07 PM
|Shkreli Gives Zosano a Giant Headache|
finance.yahoo.com - April 7 at 1:41 PM
|Zosano Pharma Corp (ZSAN) Receives New Coverage from Analysts at Piper Jaffray Companies|
www.americanbankingnews.com - March 30 at 8:23 AM
|Zosano Pharma Corp (ZSAN) Short Interest Update|
www.americanbankingnews.com - March 28 at 7:07 AM
Zosano Pharma Corporation (ZSAN) Chart for Friday, September, 22, 2017